Apnimed (APMD)
Develops Oxnimbi, an oral therapy under FDA review for obstructive sleep apnea.
Something off on this page? Send us feedback.
Develops Oxnimbi, a once-nightly oral combination under FDA review for obstructive sleep apnea, and is preparing a U.S. prescription-drug launch if approved. Its sole clinical candidate makes prospective product sales dependent on regulatory clearance and commercial execution.
Develops oral therapies for sleep-related breathing disease, centered on AD109, or Oxnimbi, a once-nightly fixed-dose combination under FDA review for adults with obstructive sleep apnea. The treatment is designed to maintain upper-airway muscle activity during sleep and prevent airway collapse. Early, unnamed programs target related disorders and comorbidities.
Prepares commercial, medical-affairs, market-access, manufacturing, sales, marketing, and distribution capabilities for a possible focused U.S. launch. Oxnimbi is the sole clinical candidate and has not been approved, leaving prospective prescription-drug sales dependent on FDA action, treatment acceptance, payer coverage, contract manufacturers, and licensed patents from Brigham and Women’s Hospital.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Not reported.
No dividends on record.
No ownership filings on record for this listing.
- ResMed
First-line PAP standard competing for OSA treatment adoption.
- Eli Lilly
Approved drug option for obesity-related moderate-to-severe OSA.
- Inspire Medical Systems
Implantable alternative for moderate-to-severe OSA after PAP.
- Incannex Healthcare
Nearest oral fixed-dose drug challenger in OSA development.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Apnimed | $21.92 | −14.07% | $1.02B | — | — | — | — |
| ResMed | $221.78 | −0.09% | $32.20B | 21.3 | 18.3 | 5.7 | +8.6% |
| Eli Lilly | $1,151.84 | −1.56% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Inspire Medical Systems | $68.86 | −3.42% | $2.06B | 15.4 | 53.4 | 2.3 | −7.6% |
| Incannex Healthcare | $3.45 | +1.62% | $40.6M | — | — | — | +1,566.7% |
| Median | 21.3 | 28.2 | 5.7 | +28.1% |